obesity drug news today glp-1 october 27 2025 Drugmakers are racing to find the next Wegovy. These trials are ones to watch Overview of GLP-1s

Will we develop oral or longer-acting versions

But physicians are cautioning that these are serious medications not a cosmetic quick fix

But researchers cautioned that the observational study doesn't prove the popular weight-loss drugs reduce cancer risk

Thirty-four reported adverse effects, including hypersensitivity, injection-site reactions, pruritus, urticaria, angioedema, and immune-mediated conditions like bullous pemphigoid

If you accidentally inject into muscle instead of fat, the medication absorbs faster than intended

Use of glucagon-like peptide 1 agonists for weight loss compared with bupropion-naltrexone was associated with an increased risk for pancreatitis, gastroparesis and bowel obstruction but not biliary disease, researchers reported in JAMA